Skip to content

Allo - Cancer - Thrombosis

Allo - Cancer - Thrombosis

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03563924
Acronym
AlloTC
Enrollment
100
Registered
2018-06-20
Start date
2018-06-30
Completion date
2019-09-30
Last updated
2018-06-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer, Venous Thromboembolism

Brief summary

Management of venous thromboembolism (VTE) in patients with cancer is complex and require the intervention of many specialized health professionals, in hospital but also at home and during follow-up. The AlloTC project aims to integrate the management of VTE within the multidisciplinary care pathway of the patient with cancer, in order to improve the management of VTE in patients with cancer: optimize treatments and follow-up with appropriate anticoagulants, monitor the implementation of good clinical practice, promote patient involvement and adherence. The objective of this monocentric study is to evaluate the efficiency of the integration of the therapeutic management of VTE into a specific management of patient with cancer and to set up a specialized AlloTC team that coordinates this course of care. For that purpose, the management of VTE and outcome of patients with cancer and VTE will be compared between two periods : traditional management and management with the AlloTC team.

Interventions

OTHERSetting up a specific care path AlloTC for management of TVE in patients with cancer

Setting up a specific care path AlloTC for management of TVE in patients with cancer with a specific coordination nurse within the AlloTC multidisciplinary team as a privileged interlocutor for health professionals and patients with the aim of simplifying the care pathways and ensuring a hospital-city interface organized in collaboration with the attending physician, to develop and publicize tools available for patients and caregivers (information documents, patient monitoring protocols, etc.)

Sponsors

Assistance Publique - Hôpitaux de Paris
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
OTHER

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Diagnosis of cancer or haematological malignancies * Venous thromboembolism diagnosis (symptomatic or not)

Exclusion criteria

* Life expectancy ≤ 3 months * Inability to understand or sign consent * Inability to read or understand the French language

Design outcomes

Primary

MeasureTime frameDescription
Percentage of patients with appropriate care of venous thromboembolismat 6 monthsPercentage of patients who received appropriate care of venous thromboembolism according to the latest International Good Clinical Practice (GCP) guidelines

Secondary

MeasureTime frameDescription
Percentage of patients with appropriate care of venous thromboembolismat inclusionPercentage of patients who received appropriate care of venous thromboembolism according to the latest International Good Clinical Practice (GCP) guidelines
Number of calls from health professionals to the AlloTC teamat 6 months
Number of patients lost to follow-upat 3 months
Number of patients referred to the coordinating nurse in Oncology serviceat 6 monthsNumber of patients referred to the coordinating nurse in Oncology service to reassess the need for supportive care and involve health professionals (dietitian, social worker, psychologist)
Number of complicationsat 3 monthsRecurrence of venous thromboembolism and bleeding episodes.
Caregiver satisfaction survey concerning on the AlloTC team and care pathat inclusion
Number of patients evaluated at multidisciplinary meetingat 3 months
Number of patients accessing the venous thromboembolism information documents.at 6 months
Percentage of patients who had at least 1 session of specialized therapeutic educationat 6 months
Assessment of the quality of life of the patientat inclusionThe quality of life of each patient will be evaluate using the quality of life scale 'EORTC QLC-30'
Patient satisfaction survey concerning the AlloTC team and care pathat inclusion
Number of hospitalizations in the AlloTC cohortat 3 months
Hospitalization duration in the AlloTC cohortat 3 months
Number of patients under care for venous thromboembolism integrated into a personalized care plan as defined in the '' 2009-2013 Cancer Plan ''at 3 months

Contacts

Primary ContactDominique Farge
dominique.farge-bancel@aphp.fr+33142499768
Backup ContactMatthieu Resche-Rigon
matthieu.resche-rigon@univ-paris-diderot.fr+33142499747

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026